OncoCyte Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

OncoCyte wird ein Gewinn- und Umsatzwachstum von 29.6% bzw. 106.1% pro Jahr prognostiziert, während der Gewinn pro Aktie um 44.3% pro Jahr wachsen soll.

Wichtige Informationen

29.6%

Wachstumsrate der Gewinne

44.3%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.3%
Wachstumsrate der Einnahmen	106.1%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	18 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Is OncoCyte (NASDAQ:OCX) In A Good Position To Invest In Growth?

Oct 28

Oncocyte stock jumps ~15% after hours on contract for lung-cancer detection test

Aug 30

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:OCX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	6	-21	N/A	N/A	2
12/31/2025	1	-24	N/A	N/A	2
12/31/2024	1	-34	N/A	N/A	2
9/30/2024	1	-44	-20	-20	N/A
6/30/2024	1	-37	-18	-18	N/A
3/31/2024	1	-40	-19	-19	N/A
12/31/2023	2	-26	-24	-23	N/A
9/30/2023	1	-22	-29	-29	N/A
6/30/2023	1	-17	-38	-36	N/A
3/31/2023	1	-11	-43	-41	N/A
12/31/2022	1	-19	-50	-46	N/A
9/30/2022	-1	-22	-47	-43	N/A
6/30/2022	0	-34	-46	-43	N/A
3/31/2022	1	-43	-42	-39	N/A
12/31/2021	2	-44	-38	-36	N/A
9/30/2021	5	-35	-37	-35	N/A
6/30/2021	4	-28	-32	-30	N/A
3/31/2021	2	-26	-31	-29	N/A
12/31/2020	1	-30	-27	-26	N/A
9/30/2020	1	-32	-27	-25	N/A
6/30/2020	0	-30	-25	-24	N/A
3/31/2020	0	-26	-21	-20	N/A
12/31/2019	N/A	-22	-21	-20	N/A
9/30/2019	N/A	-19	-17	-17	N/A
6/30/2019	N/A	-17	-15	-14	N/A
3/31/2019	N/A	-16	-16	-16	N/A
12/31/2018	N/A	-16	-12	-12	N/A
9/30/2018	N/A	-15	-13	-13	N/A
6/30/2018	N/A	-19	N/A	-14	N/A
3/31/2018	N/A	-18	N/A	-13	N/A
12/31/2017	N/A	-19	N/A	-13	N/A
9/30/2017	N/A	-19	N/A	-13	N/A
6/30/2017	N/A	-14	N/A	-10	N/A
3/31/2017	N/A	-13	N/A	-9	N/A
12/31/2016	N/A	-11	N/A	-8	N/A
9/30/2016	N/A	-12	N/A	-7	N/A
6/30/2016	N/A	-11	N/A	-7	N/A
3/31/2016	N/A	-10	N/A	-6	N/A
12/31/2015	N/A	-9	N/A	-4	N/A
9/30/2015	N/A	-7	N/A	-3	N/A
6/30/2015	N/A	-5	N/A	-2	N/A
3/31/2015	N/A	-5	N/A	-1	N/A
12/31/2014	N/A	-5	N/A	-1	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: OCX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: OCX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: OCX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: OCXDie Einnahmen des Unternehmens (106.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: OCXDie Einnahmen des Unternehmens (106.1% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von OCX in 3 Jahren voraussichtlich hoch sein wird

OncoCyte Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus forecasts updated

Price target decreased to US$2.13

Consensus forecasts updated

Price target decreased to US$3.61

Price target decreased to US$5.02

Consensus revenue estimates fall by 28%

Recent updates

OncoCyte Corporation to Report Q3, 2024 Results on Nov 12, 2024

Oncocyte's DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial

OncoCyte Corporation announced that it expects to receive $10.203435 million in funding from Bio-Rad Laboratories, Inc.

OncoCyte Corporation has completed a Follow-on Equity Offering in the amount of $0.316184 million.

OncoCyte Corporation has filed a Follow-on Equity Offering in the amount of $7.5 million.

OncoCyte Corporation to Report Q2, 2024 Results on Aug 08, 2024

Oncocyte Announces Notice of Prior Non-Compliance and Subsequent Compliance with Nasdaq Listing Rules 5605(b)(1) and 5605(c)(2)

OncoCyte Corporation announced that it expects to receive $3.5 million in funding from Bio-Rad Laboratories, Inc.

OncoCyte Corporation Appoints Andrea James as Chief Financial Officer

Oncocyte Corporation Announces Promising Results in A Phase 2 Clinical Trial

Oncocyte Corporation Announces Favorable Oncocyte Vitgraft Kidney Study Results

OncoCyte Corporation to Report Q1, 2024 Results on May 15, 2024

OncoCyte Corporation, Annual General Meeting, Jun 28, 2024

OncoCyte Corporation announced that it has received $15.8 million in funding

Broadwood Capital, Inc. Engages with OncoCyte Corporation

OncoCyte Corporation announced that it expects to receive $15.8 million in funding

OncoCyte Corporation announced delayed annual 10-K filing

Oncocyte Corporation Begins FDA Submissions Process for VitaGraft Transplant Assays

OncoCyte Corporation to Report Q3, 2023 Results on Nov 09, 2023

Oncocyte Corporation Announces Vitagraft Kidney Transplant Diagnostic Test Receives Cms Coverage

Oncocyte Corporation Announces Executive Changes

OncoCyte Regains Compliance with Nasdaq Listing Requirements

OncoCyte Corporation to Report Q2, 2023 Results on Aug 10, 2023

Oncocyte Corporation Announces the Publication of New Data Demonstrating Vitagraft Kidney's Novel Ability to Help Physicians Treat Kidney Transplant Patients

Oncocyte Announces 1-For-20 Reverse Stock Split to Regain Compliance with Minimum Bid Price Requirement

Jennifer Levin Carter and John Peter Gutfreund Not to Stand for Re-Election to the Board of Directors of OncoCyte Corporation

OncoCyte Corporation, Annual General Meeting, Jun 23, 2023

OncoCyte Receives Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

Oncocyte Applies to Transfer the Listing of its Common Stock from The Nasdaq Global Market to The Nasdaq Capital Market

OncoCyte Corporation Announces Reduction of Workforce

OncoCyte Corporation Announces Executive Changes

Melinda Griffith Notifies Oncocyte Corporation F Her Resignation from the Board, Effective January 1, 2023

Consensus forecasts updated

High number of new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$2.13

OncoCyte Corporation to Report Q3, 2022 Results on Nov 10, 2022

Is OncoCyte (NASDAQ:OCX) In A Good Position To Invest In Growth?

Oncocyte Corporation Appoints James Liu as Controller and Principal Accounting Officer

Oncocyte Announces Unanimous Recommendation from the Advisory Panel for Clinical Diagnostic Laboratory Tests on Determarx to CMS

Oncocyte stock jumps ~15% after hours on contract for lung-cancer detection test

Oncocyte Announces Publication of the Validation of DetermaIO in Predicting Immune Therapy Response in Metastatic Bladder Cancer

Independent Chairman recently bought US$144k worth of stock

OncoCyte Corporation Receives Non-Compliance Letter from Nasdaq

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

OncoCyte Corporation Appoints Anish John as Chief Financial Officer

OncoCyte Corporation Announces the Appointment of John Peter Gutfreund as Independent Member of its Board of Directors

OncoCyte Corporation to Report Q2, 2022 Results on Aug 10, 2022

OncoCyte Corporation Announces Resignation of Li Yu as Controller and Principal Accounting Officer

OncoCyte Corporation(NasdaqGM:OCX) dropped from Russell 2000 Dynamic Index

OncoCyte Corporation, Annual General Meeting, Jul 15, 2022

Consensus forecasts updated

Price target decreased to US$3.61

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Oncocyte Corporation Completes Validation of TheraSure™ Transplant Monitor Test

Revisiting OncoCyte Corp.

High number of new directors

Price target decreased to US$5.02

Broadwood Capital Engages in Discussions with OncoCyte Corporation

OncoCyte Corporation has completed a Follow-on Equity Offering in the amount of $35.000001 million.

Consensus revenue estimates fall by 28%

Full year 2021 earnings: EPS exceeds analyst expectations

OncoCyte Corporation to Report Q4, 2021 Results on Mar 10, 2022

Is OncoCyte (NASDAQ:OCX) Using Debt Sensibly?

OncoCyte Corporation Announces Peer-Reviewed Publication in Cancers Showing Utility of DetermaCNI™ Blood-Only Monitoring Test to Detect Recurrence Following Surgery in Epithelial Ovarian Cancer

Price target decreased to US$7.80

Price target decreased to US$8.00

Oncocyte Corporation Announces Results from DetermaIO™ Test

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.10 loss in 3Q 2020)